Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Connect with me

Research groups

Research Themes

Clinical Trials

NuTIDE:701: A two-part, Phase 1 open-label dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-7738, a nucleotide analogue, in participants with advanced solid tumours. 

RDXC004/0001: A Modular, Multi-arm, Multi-part, Phase 1/2a, Adaptive Design Study to Evaluate the Safety and Tolerability of RXC004, Alone and in Combination with Anti-cancer Treatments, in Patients with Advanced Malignancies

BGB149-102: A Phase 1b, Multicentre, Multiple Ascending Dose, Safety, Pharmacokinetic and
Pharmacodynamic Study of Tilvestamab (BGB149) in Relapsed AXL-positive, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Patients

NX-1607-101: A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types

NuTide 302: A Phase Ib open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment.

ASTX029-01: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

ART0380/REFMAL: A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors  

UCB6114: Phase 1/2 Open-Label, Multicentre Study To Assess The Safety, Pharmacokinetics and Anti-tumor Activity of UCB6114 Administered Intravenously To Participants With Advanced Solid Tumors.

Sarah Blagden


Professor of Experimental Oncology

  • Lead for Oxford Cancer Trials Office (OCTO)
  • Interim chair for Athena Swan Committee (Department of Oncology)

Clinician-scientist with a specialist interest in cancer clinical trials and research group leader (RNA biology).

Research Summary

Investigating post-transcriptional mechanisms that drive cancer behaviour, particularly the transition from precancer to invasive cancer and researching novel cancer preventives and therapeutics.


Following medical training, Sarah undertook subsequent specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital, London. Sarah was awarded a CRUK Junior Clinician Scientist PhD fellowship to study fruit fly genetics at Cambridge University (2000-2004) and later held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.

She was appointed as Senior Lecturer and Honorary Consultant at Imperial College in 2006 where she specialised in treating gynaecological cancers, launched Imperial's Early Phase Trial portfolio and established her laboratory studying the dysregulation of mRNA translation in cancer. In 2015 she moved to Oxford University and is now a Professor of Experimental Oncology. Sarah was Director of the Early Phase Clinical Trials Unit until 2021 when she took over leadership of the Oxford Clinical Trials Office (OCTO) running a national trials portfolio specialising in early phase, Precision Prevention and Early Detection studies. She has been chief or principal investigator for a number of national and international clinical studies and her team's research focus is post-transcriptional gene regulation in precancer progression. 

Group Members

James Chettle, Postdoctoral Researcher
Zinaida Dedeic, Postdoctoral Researcher 
Miriam Dixon-Zegeye, DPhil Student
Chenwan Jin, DPhil Student